A subgroup analysis of the Phase 3 STRATUM trial of roflumilast topical foam, 0.3% (Zoryve, Arcutis) in seborrheic dermatitis showed consistent efficacy across various racial and ethnic groups, as well as Fitzpatrick skin types.
In this video, Raj Chovatiya, MD, PhD, Founder and Director of the Center for Medical Dermatology and Immunology Research in Chicago, IL, discusses how the new findings affect patient care.
“Patients oftentimes ask, ‘Was it studied in people like me, and what do you expect in some of my skin type or my hair type?’ and from the data we’ve seen to date, including this analysis, it really tells us that roflumilast foam sure feels like a one-size-fits-all solution as an easy-to-apply non-steroidal across a whole diverse spectrum of patients,” he says.
The study also showed that treatment improved pigmentary changes associated with seborrheic dermatitis, which is a big concern for patients with darker skin tones. The findings were presented at the 2025 European Academy of Dermatology and Venereology (EADV) Conference in Paris, France.
